{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T09:11:47Z","timestamp":1792228307829,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ebiom.2023.104662","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T17:35:14Z","timestamp":1687455314000},"page":"104662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"special_numbering":"C","title":["Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7179-0335","authenticated-orcid":false,"given":"Amit","family":"Bar-Or","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian-Andrea","family":"Thanei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Harp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Bonati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0829-7569","authenticated-orcid":false,"given":"Anne H.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saloumeh","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gaetano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4932-4001","authenticated-orcid":false,"given":"Stephen L.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Kappos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Leppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Model","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Koendgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ebiom.2023.104662_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104662_bib2","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1212\/CON.0000000000000737","article-title":"Phases and phenotypes of multiple sclerosis","volume":"25","author":"Kantarci","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"issue":"9","key":"10.1016\/j.ebiom.2023.104662_bib3","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104662_bib4","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.25463","article-title":"Silent progression in disease activity-free relapsing multiple sclerosis","volume":"85","author":"Cree","year":"2019","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104662_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104662_bib8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ebiom.2023.104662_bib9","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(20)30342-2","article-title":"Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Wolinsky","year":"2020","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104662_bib10","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaneurol.2018.3746","article-title":"Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders","volume":"76","author":"Olsson","year":"2019","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/j.ebiom.2023.104662_bib11","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ebiom.2023.104662_bib12","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1177\/1352458515623365","article-title":"Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity","volume":"22","author":"Kuhle","year":"2016","journal-title":"Mult Scler"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104662_bib13","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1001\/jamaneurol.2020.2453","article-title":"Association of sustained immunotherapy with disability outcomes in patients with active secondary progressive multiple sclerosis","volume":"77","author":"Lizak","year":"2020","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104662_bib14","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ebiom.2023.104662_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.852563","article-title":"Prognostic value of serum neurofilament light chain for disease activity and worsening in patients with relapsing multiple sclerosis: results from the phase 3 ASCLEPIOS I and II trials","volume":"13","author":"Ziemssen","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.ebiom.2023.104662_bib16","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1212\/WNL.0000000000003653","article-title":"Serum neurofilament is associated with progression of brain atrophy and disability in early MS","volume":"88","author":"Kuhle","year":"2017","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.ebiom.2023.104662_bib17","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1177\/1352458518814117","article-title":"Slowly expanding\/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions","volume":"25","author":"Elliott","year":"2019","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104662_bib18","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s41467-020-14612-6","article-title":"Serum neurofilament light levels in normal aging and their association with morphologic brain changes","volume":"11","author":"Khalil","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104662_bib19","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.ebiom.2023.104662_bib20","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1177\/1352458517715132","article-title":"Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod","volume":"24","author":"Piehl","year":"2018","journal-title":"Mult Scler"},{"issue":"22","key":"10.1016\/j.ebiom.2023.104662_bib21","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104662_bib22","doi-asserted-by":"crossref","first-page":"e1201","DOI":"10.1212\/WNL.0000000000009097","article-title":"Blood neurofilament light levels segregate treatment effects in multiple sclerosis","volume":"94","author":"Delcoigne","year":"2020","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.ebiom.2023.104662_bib23","doi-asserted-by":"crossref","first-page":"e2120","DOI":"10.1212\/WNL.0000000000200258","article-title":"Blood neurofilament light in progressive multiple sclerosis: post hoc analysis of 2 randomized controlled trials","volume":"98","author":"Leppert","year":"2022","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104662_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.47588","article-title":"Serum neurofilament light and multiple sclerosis progression independent of acute inflammation","volume":"5","author":"Gafson","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"15","key":"10.1016\/j.ebiom.2023.104662_bib25","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.4155\/bio-2019-0163","article-title":"Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood","volume":"11","author":"Hendricks","year":"2019","journal-title":"Bioanalysis"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104662_bib26","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/acn3.51524","article-title":"Development of an age-adjusted model for blood neurofilament light chain","volume":"9","author":"Harp","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104662_bib27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"issue":"19","key":"10.1016\/j.ebiom.2023.104662_bib28","doi-asserted-by":"crossref","first-page":"e1898","DOI":"10.1212\/WNL.0000000000012752","article-title":"Serum neurofilament light association with progression in natalizumab-treated patients with relapsing-remitting multiple sclerosis","volume":"97","author":"Bridel","year":"2021","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104662_bib29","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1212\/WNL.0000000000012326","article-title":"Chronic white matter inflammation and serum neurofilament levels in multiple sclerosis","volume":"97","author":"Maggi","year":"2021","journal-title":"Neurology"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642300227X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642300227X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:25:29Z","timestamp":1762457129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235239642300227X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":27,"alternative-id":["S235239642300227X"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104662","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104662","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104662"}}